AstraZeneca Aktie
WKN: 886715 / ISIN: US0463531089
10.05.2017 08:41:39
|
AstraZeneca : Tralokinumab Fails To Meet Primary Endpoint Of Reduction In AAER
(RTTNews) - AstraZeneca plc.(AZN.L, AZN) and MedImmune, its global biologics research and development arm, said Wednesday that tralokinumab, an anti-interleukin-13 or IL-13 human monoclonal antibody, did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate or AAER in the overall population of severe, uncontrolled asthma patients, compared with placebo in STRATOS 1, the first of two pivotal Phase III trials.
In a planned analysis, a clinically-relevant reduction in AAER was observed in a sub-population of patients with an elevated biomarker associated with increased IL-13 activity. This sub-group of patients will now be the focus for the future analysis of STRATOS 2, the second ongoing pivotal Phase III trial.
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer, said "Severe asthma is a heterogeneous disease with significant unmet needs and we will now await the STRATOS 2 results in the second half of 2017 to explore the potential to treat a sub-group of uncontrolled asthma patients with tralokinumab."
The STRATOS 1 and STRATOS 2 trials evaluate the efficacy and safety of tralokinumab in reducing the rate of asthma exacerbations in adults and adolescents with severe asthma, inadequately controlled despite receiving inhaled corticosteroids (ICS) plus long-acting beta2-agonist (LABA). STRATOS 1 explored the potential to use biomarkers to identify patients with an enhanced response to tralokinumab. STRATOS 2 is designed to validate the biomarker population identified in STRATOS 1.
Potential future regulatory submissions for tralokinumab will be dependent on the combined analysis of both STRATOS 1 and STRATOS 2, the two pivotal trials in the ATMOSPHERE clinical programm.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AstraZeneca PLC (spons. ADRs)mehr Nachrichten
14.04.25 |
Erste Schätzungen: AstraZeneca informiert über die jüngsten Quartalsergebnisse (finanzen.net) | |
11.04.25 |
Gute Stimmung in New York: NASDAQ 100 schlussendlich freundlich (finanzen.at) | |
11.04.25 |
Pluszeichen in New York: NASDAQ 100 verbucht nachmittags Gewinne (finanzen.at) | |
11.04.25 |
Börse New York: So steht der NASDAQ 100 aktuell (finanzen.at) | |
11.04.25 |
Aufschläge in New York: NASDAQ 100 verbucht zum Handelsstart Zuschläge (finanzen.at) | |
10.04.25 |
Schwacher Wochentag in New York: NASDAQ 100 schließt weit in der Verlustzone (finanzen.at) | |
10.04.25 |
Börse New York in Rot: NASDAQ 100-Anleger treten am Nachmittag Rückzug an (finanzen.at) | |
10.04.25 |
Zurückhaltung in New York: NASDAQ 100 mit Kurseinbruch (finanzen.at) |
Analysen zu MedImmune Inc.mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 59,00 | 2,61% |
|